Back to Type 2 Diabetes
This trial is complete. It is no longer accepting participants. Results may be available on ClinicalTrials.gov.

NCT00153179

NCT00153179
Completed Phase 2

Who may be able to join

Who might be able to join this trial:

  • People who have been diagnosed with type 2 diabetes (as defined by the National Diabetes Data Group)
  • People who have a normal heart and blood vessel check-up result
  • People who have not smoked for at least 1 year before joining
  • Healthy volunteers with no known medical problems
  • Healthy volunteers with a normal heart and blood vessel check-up result
  • Healthy volunteers whose fasting blood sugar level is below 110 mg/dL
  • Healthy volunteers who have not smoked for at least 1 year before joining

Who may not be able to join:

For people with type 2 diabetes:

  • People with high blood pressure that is not being treated (above 140/90 mmHg)
  • People with high cholesterol that is not being treated (LDL above the 75th percentile for their age)
  • People who have smoked cigarettes within the past year
  • People who have nerve damage that requires medication
  • People who have kidney problems, including high levels of protein in the urine or high creatinine levels in the blood
  • People with an abnormal heart or blood vessel check-up result
  • People who have taken a type of diabetes medication called a thiazolidinedione within the past year
  • Women who have gone through menopause and are taking hormone replacement therapy
  • People taking ACE inhibitors or angiotensin receptor blockers (a type of blood pressure medication) should be aware that they may need to stop these for 2 weeks before taking the study drug (confirm with trial site)

For healthy volunteers:

  • People with an abnormal heart or blood vessel check-up result
  • People who are currently taking any prescription medications
  • People whose fasting blood sugar level is 110 mg/dL or higher
  • People who have smoked cigarettes within the past year

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Trial details

Status
Completed
Phase
Phase 2
Sponsor
Brigham and Women's Hospital
Registry
clinicaltrials_gov
Start date
1 September 2005
Est. completion
1 December 2011

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Flow-mediated Dilation After Placebo or Acipimox Treatment Between Healthy Controls and Those With Metabolic Syndrome; Difference in Insulin-mediated Skeletal Muscle Glucose Utilization Between Test Agent and Placebo

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

View original record on ClinicalTrials.gov